Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.

doi:10.1158/1078-0432.CCR-21-4504

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Sept 2022

Nathenson Michael J, Hu Junxiao, Ratan Ravin, Somaiah Neeta, Hsu Robert, DeMaria Peter J, Catoe Heath W, Pang Angela, Subhawong Ty K, Amini Behrang, Sweet Kevin, Feister Katharina, Malik Karan, Jagannathan Jyothi, Braschi-Amirfarzan Marta, Sheren Jamie, Caldas Yupanqui, Moreno Tellez Cristiam, Rosenberg Andrew E, Lazar Alexander J, Maki Robert G, Benedetto Pasquale, Cohen Jonathan, Trent Jonathan C, Ravi Vinod, Patel Shreyaskumar, Wilky Breelyn A

Abstract excerpt

PURPOSE: Determine whether specific CTNNB1 or APC mutations in patients with desmoid tumor were associated with differences in clinical responses to systemic treatments. EXPERIMENTAL DESIGN: We established a multi-institutional dataset of previously treated patients with desmoid tumor across four U.S. sarcoma centers, including demographic and clinicopathologic characteristics, treatment regimens, and clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to beta Catenin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Desmoid Tumors

Share to High-Throughput Nucleotide Sequencing

Share to Mutation

Share to Prognosis

Share to Sarcoma Diagnosis and Treatment

Share to Soft tissue tumor case studies

Share to Tumors and Oncological Cases

Source

Open in PubMed Open full text

Identifiers

PMID: 35180772
DOI: 10.1158/1078-0432.CCR-21-4504
PMCID: PMC9475245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Systemic Chemotherapies Retain Antitumor Activity in Desmoid Tumors Independent of Specific Mutations in CTNNB1 or APC: A Multi-institutional Retrospective Study.PMID 35180772Read ↗

CTNNB1 S45F Mutation Predicts Poor Efficacy of Meloxicam Treatment for Desmoid Tumors: A Pilot StudySemantic proximity Read ↗

Multi-Layered Molecular Profiling Informs the Diagnosis and Targeted Therapy of Desmoplastic Small Round Cell TumorSemantic proximity Read ↗

Multi-site desmoplastic small round cell tumors are genetically related and immune-coldSemantic proximity Read ↗

Optimal therapy for desmoid tumors: current options and challenges for the future.Semantic proximity Read ↗

Desmoplastic Small Round Cell Tumor: A Review of Main Molecular Abnormalities and Emerging TherapySemantic proximity Read ↗

Autophagy inhibition overcomes sorafenib resistance in S45F‐mutated desmoid tumorsSemantic proximity Read ↗

Profiling of desmoid tumors reveals frequent mutations in chromatin-remodeling genes and identifies an Immune-myogenic subtype.Semantic proximity Read ↗

Trends in diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: Japanese musculoskeletal oncology group questionnaire survey.Semantic proximity Read ↗

Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis).Semantic proximity Read ↗

Establishment and characterization of NCC-DSM1-C1: a novel cell line derived from a patient with desmoid fibromatosis.Semantic proximity Read ↗

Does the Addition of Mutations of CTNNB1 S45F to Clinical Factors Allow Prediction of Local Recurrence in Patients With a Desmoid Tumor? A Local Recurrence Risk Model.Semantic proximity Read ↗

CTNNB1 Mutational analysis enhances diagnostic precision in β-catenin-negative desmoid fibromatosis: a clinicopathological and molecular study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.